Development of next generation drugs for chronic myeloid leukaemia

慢性粒细胞白血病(CML)是四种最常见的白血病之一。在目前的治疗方法下，新诊断的CML患者中有15%-20%将在未来五年内死亡，因此发现新的治疗方法至关重要。本项目的目的是基于新的治疗方法(即不同类型的分子和不同的结合部位)开发新一代治疗慢性粒细胞白血病的药物，以对抗现有治疗方法获得的耐药性。

Chronic myeloid leukaemia (CML) is one of the four most common types of leukaemia. With current therapies, 15–20% of patients newly diagnosed for CML will die in the next five years, and it is therefore vitally important to discover new treatments. The aim of this project is to develop a new generation of drugs to treat CML based on new approaches (i.e., different type of molecules and different binding site) that can combat the resistance acquired to the current treatments.